Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]
Inhibrx, Inc. (INBX)
Company Research
Source: Seeking Alpha
INBX expects to release pivotal progression-free survival [PFS] data for ozekibart + FOLFIRI in heavily pretreated metastatic colorectal cancer in 2026. Ozekibart is also advancing in Ewing Sarcoma, with enrollment completion expected Q2 2026 and potential FDA meeting for accelerated approval in H2 2026. Despite positive data, INBX faces cash runway risks and potential dilution, with current funds projected to last only 12 months from the last SEC filing. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » parichat wongyai/E+ via Getty Images The last time I spoke about Inhibrx Biosciences, Inc. ( INBX ) it was in a Seeking Alpha article entitled " Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha M
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) ProgramPR Newswire
- Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap [Seeking Alpha]Seeking Alpha
- Inhibrx Biosciences (NASDAQ:INBX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
INBX
Earnings
- 8/13/25 - Beat
INBX
Analyst Actions
- 11/19/25 - Citigroup Inc.
INBX
Sec Filings
- 12/16/25 - Form 8-K
- 11/14/25 - Form 10-Q
- 11/14/25 - Form 8-K
- INBX's page on the SEC website